Short answer
Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on March 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CEO Marianne De Backer appointed to additional role of President effective March 4, 2026: consolidating top executive positions.
Vir Biotechnology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO Marianne De Backer appointed to additional role of President effective March 4, 2026: consolidating top executive positions
- No new compensation terms disclosed, no outside arrangements or conflicts of interest noted
- Role consolidation signals leaner leadership structure, typical of biotech companies managing costs or strategic transitions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vir Biotechnology, Inc. 8-K filings
Get the next VIR 8-K as it lands
Follow VIR for push alerts, or ask the research agent what this filing means.